Abstract
Background
Transthyretin cardiac amyloidosis (ATTR–CM) is an increasingly recognised cause of heart failure in older adults, but real–world data in patients aged ≥80 years are limited.
Methods
A retrospective analysis was conducted on a real–world cohort of patients aged ≥80 years with cardiac amyloidosis, as part of routine clinical practice in Amyloidosis referral center in S. Camillo–Forlanini Hospital in Rome. A comprehensive data set was collected at the time of the initial evaluation and at the subsequent follow–up, as defined by the first available clinical reassessment following the initial evaluation during routine clinical practice. This included clinical characteristics, echocardiographic findings, biomarkers, electrocardiographic features and medical therapy. The functional status and cognitive performance of the subjects were systematically assessed.